AstraZeneca Results Presentation Deck
Core profit and loss
Total revenue
- product sales
- collaboration revenue
Gross margin
Operating expenses
- R&D expenses
- SG&A expenses
Other operating income
Operating profit
Tax rate
EPS
H1 2021
$m
15,540
15,302
238
73.8%
8,511
3,439
4,870
1,309
4,329
14.3%
$2.53
$(0.04)
change
%
18
19
(12)
(6.4) pp
12
21
7
115
20
27
% total
revenue
100
98
2
55
22
31
8
28
Q2 2021
$m
8,220
8,045
175
73.0%
4,375
1,801
2,471
129
1,805
23.6%
$0.90
$(0.01)
Impact of pandemic vaccine on EPS
Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales.
22
change
%
25
27
(23)
(9.9) pp
13
24
7
(2)
5
(2)
% total
revenue
100
98
2
53
22
30
2
22
BView entire presentation